Gene · 4100
NIH grants735
NIH grants whose papers are about the gene, through NIH's grant-paper links.
81 to 100 of 735
Download this page as JSON| Grant | Title | MAGEA1 papers | Newest fiscal year |
|---|---|---|---|
| P50CA228944 | Fred Hutchinson Cancer Center Lung SPORE | 1 | 2025 |
| R01CA114536 | Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy | 1 | 2025 |
| R01CA143130 | Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal | 1 | 2025 |
| R01CA197296 | Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial | 1 | 2025 |
| R01CA200900 | Systemic RNA Delivery to Tumors | 1 | 2025 |
| R01CA221874 | Comprehensive minimal residual disease tracking in cancer | 1 | 2025 |
| R01CA238039 | Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway | 1 | 2025 |
| R01CA241752 | Targeting MUC5AC mucin in breast cancer brain metastasis | 1 | 2025 |
| R01CA257623 | FAST-FNA immune cell profiling in HNSCC | 1 | 2025 |
| R01GM072562 | Notch signaling and germline-soma interactions in the Drosophila ovarian model | 1 | 2025 |
| R01HL092577 | IDENTIFICATION OF COMMON GENETIC VARIANTS FOR ATRIAL FIBRILLATION AND PR INTERVAL | 1 | 2025 |
| R01HL127349 | Genomic Analysis of Tissue and Cellular Heterogeneity in IPF | 1 | 2025 |
| R01NS097851 | IDO1 and Immunotolerance in Glioblastoma | 1 | 2025 |
| R35CA197695 | Translating genomic discoveries to improved outcomes for high risk acute leukemia | 1 | 2025 |
| R35CA197745 | Predicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell Level | 1 | 2025 |
| R35CA220500 | Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes | 1 | 2025 |
| R35CA253175 | Determinants of response to cancer immunotherapy | 1 | 2025 |
| R35GM125005 | Chemoenzymatic Synthesis, Mode of Action and Evolution of Natural Product-based Macrocycles | 1 | 2025 |
| R35GM133557 | Folding, Misfolding, and Unfolding: How human 3D genome structure resists, adapts, or succumbs to physical stresses in health and disease | 1 | 2025 |
| R35GM133794 | Advanced molecular engineering approach for understanding extracellular vesicle in vivo trafficking mechanism | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4100/grants?page=5